Bausch Health Companies Inc's stock saw notable movements this week, amidst key updates and performance metrics.
Bausch Health Companies Inc (BHC.TO) experienced a price increase of 5.07% on Monday, though it remains down 9.84% over the past week. This fluctuation comes on the heels of significant company news and a mixed performance outlook from analysts.
Advertisement
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeAdvertisement
Market cap
$3.25B
52W high
$11.97
52W low
$6.10
1W change
-9.84%
Beta
0.38
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to fall 19.4% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-19.4% Upside
Current Price
C$8.70
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
98.4%
Annualized
90-Day Vol
64.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$10.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.23 | C$6.57 – C$12.97 |
| 60 trading days | C$9.80 | C$6.06 – C$15.84 |
| 90 trading days | C$10.40 | C$5.78 – C$18.73 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the recent developments surrounding Bausch Health, including leadership changes and earnings results, while keeping an eye on the stock's technical indicators and market sentiment.
Stock Up 5.07% on Monday, Still Down 9.84% Weekly
Bausch Health's stock has fluctuated significantly, with a recent monthly gain of 25% following a solid earnings report, yet the year-to-date performance remains negative at -12.30%.
Bull case
The recent appointment of CEO Thomas J. Appio to the Bausch + Lomb Board is a positive sign for the company. This move suggests a strategic alignment that could foster growth, especially after the strong Q2 earnings report that exceeded expectations.
Bear case
Despite the positive earnings report, analysts are concerned about the stock's bearish outlook and negative profit margin. These factors raise questions about the long-term sustainability of the stock and overall market confidence.
Recent Price Action
Advertisement
Bausch Health Companies Inc (BHC.TO) closed at C$8.83 on Monday, reflecting a daily increase of 5.07%. However, the stock has faced a challenging week, with a cumulative decline of 9.84%. Over the past month, the stock has shown resilience, gaining 25% and offering a glimmer of hope for investors amid broader market volatility.
Company News and Catalysts
Recent developments have played a significant role in influencing Bausch Health's stock performance. CEO Thomas J. Appio's appointment to the Bausch + Lomb Board has been highlighted as a positive step towards strategic direction. Additionally, the company reported strong Q2 earnings, beating estimates and raising its outlook for 2026, which contributed to the stock's recent surge.
Technical Picture
From a technical standpoint, Bausch Health is trading well above its 50-day moving average of C$7.12, reflecting a 24.0% premium. The 200-day moving average stands at C$8.10, indicating a 9.1% gain from the current price. The stock's 52-week range of C$6.10 to C$11.97 shows it is currently at 47% of this range. With a beta of 0.38, the stock is less volatile compared to the broader market, but the recent trading volume of 505,353 shares is below the 20-day average of 755,636, suggesting a lack of momentum.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
